July 25 (Reuters) - Correvio Pharma Corp CORV.TO :
* U.S. FDA ACCEPTS CORREVIO'S RESUBMITTED NEW DRUG APPLICATION FOR BRINAVESS (VERNAKALANT)
* CORREVIO PHARMA CORP - COMPANY ALSO REPORTS CERTAIN PRELIMINARY FINANCIAL RESULTS FOR Q2 2019
* CORREVIO PHARMA CORP - REVENUE FOR Q2 IS EXPECTED TO BE IN RANGE OF $7.2 TO 7.6 MILLION
* CORREVIO PHARMA CORP - NDA SEEKS APPROVAL FOR BRINAVESS FOR TREATMENT OF RECENT ONSET ATRIAL FIBRILLATION; PDUFA DATE SET FOR DECEMBER 24, 2019
* CORREVIO PHARMA CORP - AS OF JUNE 30, 2019, CORREVIO HAD CASH, CASH EQUIVALENTS AND UNRESTRICTED CASH TOTALLING APPROXIMATELY $12.9 MILLION